These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11055344)

  • 21. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa.
    Matter H; Defossa E; Heinelt U; Blohm PM; Schneider D; Müller A; Herok S; Schreuder H; Liesum A; Brachvogel V; Lönze P; Walser A; Al-Obeidi F; Wildgoose P
    J Med Chem; 2002 Jun; 45(13):2749-69. PubMed ID: 12061878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ecotin: a serine protease inhibitor with two distinct and interacting binding sites.
    Yang SQ; Wang CI; Gillmor SA; Fletterick RJ; Craik CS
    J Mol Biol; 1998 Jun; 279(4):945-57. PubMed ID: 9642073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of glycolic and mandelic acid derivatives as factor Xa inhibitors.
    Su T; Wu Y; Doughan B; Kane-Maguire K; Marlowe CK; Kanter JP; Woolfrey J; Huang B; Wong P; Sinha U; Park G; Malinowski J; Hollenbach S; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2279-82. PubMed ID: 11527714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state factor Xa inhibitors.
    Su T; Yang H; Volkots D; Woolfrey J; Dam S; Wong P; Sinha U; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Feb; 13(4):729-32. PubMed ID: 12639568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Wang S; Fevig JM; Quan ML; Amparo E; Cacciola J; Rossi KA; Alexander RS; Smallwood AM; Luettgen JM; Liang L; Aungst BJ; Wright MR; Knabb RM; Wong PC; Wexler RR; Lam PY
    J Med Chem; 2001 Feb; 44(4):566-78. PubMed ID: 11170646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel benzo-fused lactam scaffolds as factor Xa inhibitors.
    Tamura SY; Goldman EA; Bergum PW; Semple JE
    Bioorg Med Chem Lett; 1999 Sep; 9(17):2573-8. PubMed ID: 10498211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.
    Jia ZJ; Wu Y; Huang W; Goldman E; Zhang P; Woolfrey J; Wong P; Huang B; Sinha U; Park G; Reed A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1651-5. PubMed ID: 12039583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
    Hirayama F; Koshio H; Ishihara T; Watanuki S; Hachiya S; Kaizawa H; Kuramochi T; Katayama N; Kurihara H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2002 Aug; 10(8):2597-610. PubMed ID: 12057649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of aminophenol-based factor Xa inhibitors.
    Wu S; Guilford WJ; Chou YL; Griedel BD; Liang A; Sakata S; Shaw KJ; Trinh L; Xu W; Zhao Z; Morrissey MM
    Bioorg Med Chem Lett; 2002 May; 12(9):1307-10. PubMed ID: 11965377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
    Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
    Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity.
    Koshio H; Hirayama F; Ishihara T; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2004 May; 12(9):2179-91. PubMed ID: 15080918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New studies on natural inhibitors of proteolytic enzymes].
    Mosolov VV
    Bioorg Khim; 1998 May; 24(5):332-40. PubMed ID: 9661786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position.
    Baettig U; Brown L; Brundish D; Dell C; Furzer A; Garman S; Janus D; Kane PD; Smith G; Walker CV; Cockcroft X; Ambler J; Mitchelson A; Talbot MD; Tweed M; Wills N
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1563-6. PubMed ID: 10915051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.
    Guertin KR; Gardner CJ; Klein SI; Zulli AL; Czekaj M; Gong Y; Spada AP; Cheney DL; Maignan S; Guilloteau JP; Brown KD; Colussi DJ; Chu V; Heran CL; Morgan SR; Bentley RG; Dunwiddie CT; Leadley RJ; Pauls HW
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1671-4. PubMed ID: 12039587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.
    Koshio H; Hirayama F; Ishihara T; Shiraki R; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Kaku S; Katayama N; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2005 Feb; 13(4):1305-23. PubMed ID: 15670939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
    Shi Y; Sitkoff D; Zhang J; Han W; Hu Z; Stein PD; Wang Y; Kennedy LJ; O'Connor SP; Ahmad S; Liu EC; Seiler SM; Lam PY; Robl JA; Macor JE; Atwal KS; Zahler R
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5952-8. PubMed ID: 17855089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridines.
    Ng HP; Buckman BO; Eagen KA; Guilford WJ; Kochanny MJ; Mohan R; Shaw KJ; Wu SC; Lentz D; Liang A; Trinh L; Ho E; Smith D; Subramanyam B; Vergona R; Walters J; White KA; Sullivan ME; Morrissey MM; Phillips GB
    Bioorg Med Chem; 2002 Mar; 10(3):657-66. PubMed ID: 11814853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alteration of the specificity of ecotin, an E. coli serine proteinase inhibitor, by site directed mutagenesis.
    Pál G; Sprengel G; Patthy A; Gráf L
    FEBS Lett; 1994 Mar; 342(1):57-60. PubMed ID: 8143850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.